[HTML][HTML] Targeting the biology of aging with mTOR inhibitors
JB Mannick, DW Lamming - Nature Aging, 2023 - nature.com
Inhibition of the protein kinase mechanistic target of rapamycin (mTOR) with the Food and
Drug Administration (FDA)-approved therapeutic rapamycin promotes health and longevity …
Drug Administration (FDA)-approved therapeutic rapamycin promotes health and longevity …
[HTML][HTML] Acute lymphoblastic leukemia: a comprehensive review and 2017 update
T Terwilliger, M Abdul-Hay - Blood cancer journal, 2017 - nature.com
Acute lymphoblastic leukemia (ALL) is the second most common acute leukemia in adults,
with an incidence of over 6500 cases per year in the United States alone. The hallmark of …
with an incidence of over 6500 cases per year in the United States alone. The hallmark of …
[HTML][HTML] Standards and guidelines for the interpretation and reporting of sequence variants in cancer: a joint consensus recommendation of the Association for …
Widespread clinical laboratory implementation of next-generation sequencing–based
cancer testing has highlighted the importance and potential benefits of standardizing the …
cancer testing has highlighted the importance and potential benefits of standardizing the …
Genetic basis of acute lymphoblastic leukemia
I Iacobucci, CG Mullighan - Journal of Clinical Oncology, 2017 - ascopubs.org
Acute lymphoblastic leukemia (ALL) is the most common childhood cancer, and despite cure
rates exceeding 90% in children, it remains an important cause of morbidity and mortality in …
rates exceeding 90% in children, it remains an important cause of morbidity and mortality in …
Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia
KG Roberts, Y Li, D Payne-Turner… - New England journal …, 2014 - Mass Medical Soc
Background Philadelphia chromosome–like acute lymphoblastic leukemia (Ph-like ALL) is
characterized by a gene-expression profile similar to that of BCR–ABL1–positive ALL …
characterized by a gene-expression profile similar to that of BCR–ABL1–positive ALL …
CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia
SL Maude, DT Teachey, DL Porter… - Blood, The Journal of …, 2015 - ashpublications.org
Relapsed and refractory acute lymphoblastic leukemia (ALL) remains difficult to treat, with
minimal improvement in outcomes seen in more than 2 decades despite advances in upfront …
minimal improvement in outcomes seen in more than 2 decades despite advances in upfront …
High frequency and poor outcome of Philadelphia chromosome–like acute lymphoblastic leukemia in adults
KG Roberts, Z Gu, D Payne-Turner… - Journal of Clinical …, 2017 - ascopubs.org
Purpose Philadelphia chromosome (Ph)–like acute lymphoblastic leukemia (ALL) is a high-
risk subtype of childhood ALL characterized by kinase-activating alterations that are …
risk subtype of childhood ALL characterized by kinase-activating alterations that are …
Ph-like acute lymphoblastic leukemia: a high-risk subtype in adults
N Jain, KG Roberts, E Jabbour, K Patel… - Blood, The Journal …, 2017 - ashpublications.org
Philadelphia chromosome (Ph)-like acute lymphoblastic leukemia (ALL) is a high-risk
subtype of ALL in children. There are conflicting data on the incidence and prognosis of Ph …
subtype of ALL in children. There are conflicting data on the incidence and prognosis of Ph …
Philadelphia chromosome–like acute lymphoblastic leukemia
Philadelphia chromosome (Ph)-like acute lymphoblastic leukemia (ALL), also referred to as
BCR-ABL1–like ALL, is a high-risk subset with a gene expression profile that shares …
BCR-ABL1–like ALL, is a high-risk subset with a gene expression profile that shares …
Targetable kinase gene fusions in high-risk B-ALL: a study from the Children's Oncology Group
SC Reshmi, RC Harvey, KG Roberts… - Blood, The Journal …, 2017 - ashpublications.org
Philadelphia chromosome-like (Ph-like) acute lymphoblastic leukemia (ALL) is a high-risk
subtype characterized by genomic alterations that activate cytokine receptor and kinase …
subtype characterized by genomic alterations that activate cytokine receptor and kinase …